Prot #1490-0004: A Phase IIa/IIb, Randomised, Double Blind, Placebo-Controlled, Parallel-Group DoseFinding Study to Examine the Efficacy and Safety of BI 1839100 Administered Orally Over a 12-Week Treatment Period in Patients with Idiopathic Pulmonary Fib

Project: Research project

Project Details

StatusActive
Effective start/end date12/16/24 → 12/16/27

Funding

  • Boehringer Ingelheim Pharmaceuticals, Inc. (Prot #1490-0004)